Clinical Trials10 September 2026
Semaglutide Trial Data in Early Alzheimer Disease Shows a Signal
The primary endpoint data from the EVOKE and EVOKE Plus trials, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in late 2024 and subsequently reported in Nature Medicine (2025), show that semaglutide (Novo Nordisk; Ozempic at 1mg subcutaneous weekly)…
Research9 September 2026
What the evidence shows about BPC-157 and tendons
More than 100 animal studies suggest BPC-157 helps tendons heal, yet as of 2026 not a single controlled human trial has tested whether it works in people. A US advisory panel has voted to loosen access all the same.
News25 August 2026
PCSK9 Inhibitors and LDL Reduction Beyond the Statin Ceiling
PCSK9 inhibitors reduce LDL-C by up to 60% on top of statins. Discover the mechanism, FOURIER and ODYSSEY OUTCOMES trial findings, and UK NICE access criteria.
Clinical Trials20 August 2026
Personalised Cancer Vaccines Cross a Threshold: What the Melanoma Result Means for Oncology
A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.
Treatments5 August 2026
Long COVID Treatment: Where the Science Stands
Long COVID symptoms can drag on for years. Learn what's driving them and how treatments like H.E.L.P. apheresis are being used to address the underlying causes.
Research5 August 2026
MHRA Strengthen Valproate Restrictions for Women of Childbearing Potential
MHRA has reinforced valproate pregnancy restrictions for women of childbearing potential. Learn what the Pregnancy Prevention Programme requires of prescribers and pharmacists.
Technology27 July 2026
MHRA Approves Obecabtagene Autoleucel for Relapsed B-Cell Leukaemia
The MHRA has authorised obecabtagene autoleucel for relapsed B-cell leukaemia. Discover what the FELIX trial showed and what NHS access now requires.
Clinical Trials6 July 2026
DTP3 Signals A New Route for Relapsed Myeloma Care
DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?
Clinical Trials17 June 2026
Microbiome on a chip could cut drug trial failures
Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.
Clinical Trials10 June 2026
UK Clinical Trial Reforms 2026: Accelerating Approvals
The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c
Cancer4 March 2026
NHS expands abiraterone access for high-risk prostate
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because
Clinical Trials2 January 2026
AI speeds drug discovery as pharma takes risks in 2026
AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.